IBRX280121C00010000
IBRX Jan 21 2028 10.00 Call
optionOPRA
EODOct 16, 2026
3.20USD-14.439%(-0.54)677Vol10,691OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
10
Expiration
Jan 21, 2028
DTE
458d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.18 | -55.00% | 1,199 | 1,985 |
| Oct 30, 2026 | 10d | $0.32 | -54.29% | 35 | 768 |
| Nov 6, 2026 | 17d | $0.70 | -30.00% | 65 | 125 |
| Nov 13, 2026 | 24d | $0.70 | -40.68% | 9 | 38 |
| Nov 20, 2026 | 31d | $0.80 | -38.46% | 311 | 5,823 |
| Nov 27, 2026 | 38d | $1.00 | -31.03% | 3 | 86 |
| Dec 18, 2026 | 59d | $1.30 | +0.00% | 8 | 8 |
| Jan 15, 2027 | 87d | $1.55 | -26.19% | 2,280 | 72,137 |
| Mar 19, 2027 | 150d | $2.20 | -21.43% | 192 | 1,298 |
| Apr 16, 2027 | 178d | $2.10 | -27.84% | 8 | 120 |
| May 21, 2027 | 213d | $2.50 | -34.21% | 11 | 84 |
| Aug 20, 2027 | 304d | $3.48 | +2.35% | 8 | 364 |
| Nov 19, 2027 | 395d | $3.78 | -0.53% | 20 | 85 |
| Jan 21, 2028 | 458d | $3.20 | -14.44% | 677 | 10,691 |
| Mar 17, 2028 | 514d | $4.00 | +0.00% | 3 | 356 |
| Jan 19, 2029 | 822d | $4.50 | -4.46% | 6 | 2,594 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 3.5 C | $7.10 | +1.87% | 10 | 27,275 | ITM |
| 4 C | $6.75 | -1.75% | 15 | 2,170 | ITM |
| 4.5 C | $6.65 | +2.78% | 2 | 380 | ITM |
| 5 C | $5.44 | -11.54% | 4,002 | 12,523 | ITM |
| 5.5 C | $5.21 | -12.14% | 2 | 3,508 | ITM |
| 7.5 C | $4.20 | -10.64% | 9,831 | 18,015 | ITM |
| 10 C | $3.20 | -14.44% | 677 | 10,691 | OTM |
| 12 C | $2.70 | -20.59% | 16 | 1,740 | OTM |
| 15 C | $2.80 | +3.70% | 53 | 7,866 | OTM |
| 17 C | $2.82 | +4.44% | 30 | 1,006 | OTM |
| 20 C | $1.50 | -23.08% | 46 | 1,671 | OTM |
| 22 C | $1.30 | -18.75% | 185 | 8,022 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.